Mounjaro (Tirzepatide) Injection to help lower a1c for adults with type 2 diabetes MOUNJARO (TIRZEPATIDE) IS OFFICIALLY AVAILABLE IN MALAYSIA AS OF AUGUST 30, 2025, AFTER APPROVAL BY THE NATIONAL PHARMACEUTICAL REGULATORY AGENCY (NPRA)
Genetics, blood pressure, cholesterol, diabetes, smoking, kidney function, age, and lifestyle remain major determinants of cardiovascular risk
The compound has an elimination half-life of roughly 4.2 hours , meaning that plasma concentrations generally return to baseline within 12 hours
Reviewing current medications GLP-1 medications are not recommended in pregnancy Depending on the clients next steps, it may be recommended for them to discontinue the medication For next time: what to build into GLP-1 counseling Whether or not you specifically prescribe GLP-1s, increasing use makes it important to routinely assess for GLP-1 medication use among patients of reproductive age